Therapeutic implications of microRNAs in human cancer

Journal of Nucleic Acids Investigation

Volumn 2, Issue 1, 2011, Pages 17-22

  Rossbach, Michael ^a  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

microRNAs; NcRNAs; Oncogenes; Theranostics; Tumor Suppressor

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MICRORNA; MICRORNA 26A; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ARTICLE; BIOGENESIS; CANCER CHEMOTHERAPY; CANCER RESEARCH; DRUG EFFECT; DRUG SAFETY; EPIGENETICS; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC CODE; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERSONALIZED MEDICINE; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

EID: 80052195517     PISSN: None     EISSN: 20356005     Source Type: Journal    
DOI: 10.4081/jnai.2011.e3     Document Type: Article

References (61)

1. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051-60.
2. Gregory RI, Yan KP, Amuthan G, et al. The microprocessor complex mediates the genesis of microRNAs. Nature 2004;432:235-40.
3. Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science 2004;303:95-98.
4. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing, Nature 2005; 436:740-4.
5. Alvarez-Garcia I, Miska EA MicroRNA functions in animal development and human disease. Development 2005;132:4653-62.
6. Pang KC, Stephan S, Dinger ME, et al. RNA2b 2.0 - an expanded database of mammalian non-coding RNAs. Nucleic Acids Res 2007;35:D178-82.
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97.
8. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065-70.
9. Michael MZ, O'Connor SM, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003;1:882-91.
10. Takamizawa J, Konishi H, Yanagiswaw K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64:3753-6.
11. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
12. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9.
13. Cimmino A, Calin GA, Fabbri M et al. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:1394409.
14. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004.
15. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-61.
16. Scott GK, Goga A, Bhaumik D, et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007;282:1479-86.
17. Rossbach M. Small non-coding RNAs as novel therapeutics. Current Molecular Medicine 2010;4: 361-368.
18. Ma L, Teruya-Feldstein J, Weinberg RA. Tumor invasion and metastasis intiated by microRNA-10b in breast cancer. Nature 2007;449:682-8.
19. Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010;28:341-7.
20. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
21. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer disagnosis and prognosis. Cancer Cell 2006;9:189-98.
22. Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev 2009;35:328-34.
23. Lynam-Lennon N, Maher SG, Reynolds JV. The roles of microRNA in cancer and apoptosis. Biol. Rev. Camb. Philos. Soc. 2009; 84:55-71.
24. Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int. J. Cancer 2010;126:2-10.
25. Ota A, Tagawa H, Karnan S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004;64:3087-95.
26. Mendell JT. MiRiad roles for the miR-17-92 cluster in development and disease. Cell 2008;133:217-22.
27. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47.
28. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21:1025-30.
29. O'Donnell KA, Wentzel EA, Zeller KI, et al. CMyc- regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-43.
30. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007:67;7713-22.
31. Mirnezami AH, Pickard K, Zhang L, et al. MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol 2009;35:339-47.
32. Du Y, Xu Y, Ding L, et al. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol 2009;44:556-61.
33. Zhang Z, Li Z, Gao C, et al. MiR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 2008;88:1358-66.
34. Kim YK, Yu J, Han TS, et al. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res 2009;37:1672-81.
35. Petrocca F, Visone R, Onelli MR, et al. E2F1-regulated microRNAs impair TGFbetadependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008;13:272-86.
36. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004;14:1902-10.
37. Kim MS, Oh JE, Kim YR, et al. Somatic mutations and losses of expression of microRNA regulationrelated genes AGO2 and TNRC6A in gastric and colorectal cancers. J Pathol 2010;221:139-46.
38. Calin GA, Croce CM. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 2007;117:2059-66.
39. Saito Y, Suzuki H, Tsugawa H, et al. Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 2009;28:2738-244.
40. Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010;11:136-46.
41. Li X, Zhang Y, Zhang Y, et al. Survival prediction of gastric cancer by a sevenmicroRNA signature. Gut 2010;59:579-85.
42. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. ProcNatl Acad Sci USA 2008;105;10513-8.
43. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
44. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010;102:1174-9.
45. Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-9.
46. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17.
47. Rossi JJ. New hope for a microRNA therapy for liver cancer. Cell 2009;137:990-2.
48. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008;40:43-50.
49. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 2006;13:496-502.
50. Jiang Z, Guo J, Xiao B, et al. Increased expression of miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol 2010;45:17-23.
51. Cho WJ, Shin JM, Kim JS, et al. MiR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells 2009;28:521-7.
52. Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008;8:266.
53. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586-93.
54. Xia L, Zhang D, Du R, et al. MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008;123:372-9.
55. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007;59:75-86.
56. Zhao X. Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Exp Opin Drug Deliv 2009;6: 673-86.
57. Malik R, Roy L. Design and development of antisense drugs. Exp Opin Drug Discov 2008;3:1189-207.
58. Chiarantini L. Comparison of a novel delivery systems for antisense peptide nucleic acids. J Control Release 2005;109:24-36.
59. Zuhorn IS, Engberts JB, Hoeckstra D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 2007; 36:349-62.
60. Chirila, TV. The use of synthethic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 2002; 23:321-42.
61. Kotani A, Ha D, Hsieh J, et al. MiR-128b is a potent glucocorticoid sensitizer in MLLAF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 2009;114:4169-78.